

SWISSLIVER



# Jahresbericht Stiftung für Leberkrankheiten 2020

**Stiftung für Leberkrankheiten**

*Präsident:*

Prof. Dr. med. J.-F. Dufour  
[jean-francois.dufour@dbmr.unibe.ch](mailto:jean-francois.dufour@dbmr.unibe.ch)

*Administration:*

Monique Obertin  
Tel +41 31 632 87 11  
[monique.obertin@dbmr.unibe.ch](mailto:monique.obertin@dbmr.unibe.ch)

[www.swissliver.ch](http://www.swissliver.ch)

## Rückblende

Das Jahr 2020 war für die Stiftung für Leberkrankheiten trotz erschwerter Umstände im Zusammenhang mit der Corona-Pandemie aus wissenschaftlicher Sicht erfreulich. Es konnten unter anderem zwei wichtige Forschungsgrants akquiriert werden. Lediglich im Bereich der Fort- und Weiterbildung für angehende und niedergelassene Hepatologinnen und Hepatologen mussten durch die Reise-Einschränkungen Abstriche in Kauf genommen werden.

Frau Prof. Dr. med. Dr. phil. nat. Annalisa Berzigotti nahm 2019 Einsitz in den Stiftungsrat. Anlässlich der Stiftungsratssitzung vom 10.3.2020 wurde sie zur Vizepräsidentin der Stiftung gewählt. Der Stiftungsrat freut sich ausserordentlich, in Prof. Berzigotti eine sowohl wissenschaftlich wie auch persönlich engagierte Ärztin für dieses Mandat gewonnen zu haben. Prof. Berzigotti ist Leitende Ärztin der UVCM Hepatologie und verfügt über eine reiche Erfahrung in klinischer Forschung und im Management.

Seit der Jahressitzung der Stiftung am 10. 3. 2020 setzt sich der Stiftungsrat wie folgt zusammen:

- Prof. Dr. med. Jean-François Dufour, Präsident
- Prof. Dr. med. Dr. phil. nat. Annalisa Berzigotti, Vizepräsidentin
- Sébastien Baumann, Rechtsanwalt, Stiftungsrat
- Prof. Dr. med. Dr. phil. nat. Jaime Bosch, Stiftungsrat
- Dr. med. Dr. phil. nat. Ronald H.W. Lorian, MBA, Stiftungsrat
- Prof. Dr. med. Dr. phil. nat. Nikolai Naoumov, FAASLD, Stiftungsrat
- Dr. med. Michael Schenk, Stiftungsrat

Frau Dr. med. Franziska Schöni-Affolter trat per 10.3.2020 aus dem Stiftungsrat aus. Für ihr langjähriges Interesse und ihren Einsatz für unsere Stiftung dankt ihr der Stiftungsrat sehr.

Die Stiftung für Leberkrankheiten erfüllte im Berichtsjahr wiederum ihren Stiftungszweck, indem sie im Rahmen des Ordinariats für Hepatologie der Medizinischen Fakultät Bern

- leberspezifische Forschungsprojekte unterstützte
- innovative Weiter- und Fortbildungen für Ärztinnen und Ärzte auf dem Gebiet der Hepatologie anbot
- den hepatologischen Forschungsnachwuchs unterstützte
- den Unterhalt der Forschungsinfrastruktur an der Berner Hepatologie sicherstellte.

Im Einzelnen erbrachte die Stiftung die folgenden **Leistungen**:

### Löhne

1. Dr. Marie St-Pierre für ihre Arbeit am Projekt *Mitochondrial dysfunctions in NAFLD*.
2. Dr. Lange Naomi: Assistenzärztin/Doktorandin 50%, vom 1.7.20 bis 31.12.20.
3. Dr. Kolev Mirjam: Doktorandin 50%, 1.9.-31.12.20
4. Dr. Yuly Mendoza: Lohnkosten als Doktorandin vom 1.1. bis 31.12.20 (*Predictive factors of cirrhosis regression*).

### Rudolf Preisig Stipendium 2020

Pauline Fauroux, eine junge französische Aerztin, erhielt das Rudolf Preisig Stipendium 2020 zur Finanzierung ihres wissenschaftlichen Praktikums an der UVCM Hepatologie in Bern vom 1.6.-31.7.2020.

### Erwin Heinzer Stipendium 2020

Frau Dr. Blanca Norero, Hepatologin aus Chile, erhält das erstmals vergebene Erwin Heinzer Stipendium.

### Anderes

- Seit 2018 bevorschusst die Stiftung die Lohnkosten von zwei Doktorandinnen. Diese Kosten werden durch die Firma Waters an die Stiftung zurückgezahlt. Es entstehen der Stiftung dadurch keine Kosten.
- Im Zusammenhang mit dem Aufbau eines Metabolomics-Zentrums in Bern (DESI Projekt) erfolgten keine Kosten. Die Rückzahlung an die Stiftung ist erfolgt.

Wie eingangs erwähnt, konnten zwei wichtige Forschungskredite für die UVCM Hepatologie akquiriert werden:

- Gilead: *Non-Invasive Findings of Fibrotic MAFLD Patients in Diabetes Outpatient Clinic. Investigator Sponsored Research Agreement for NASH Models of Care (FIMADIA)* : Prof. Jean-François Dufour.
- Ministero della Salute, Italien: *Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome* : Prof. Annalisa Berzigotti.

### **Novartis Hepatology Training Fellowship**

Unter diesem Titel finanziert die Firma Novartis Pharma AG jungen, vielversprechenden Ärztinnen und Ärzten aus aussereuropäischen Ländern einen dreimonatigen Weiterbildungsaufenthalt an der UVCM Hepatologie in Bern. Ziel des Stipendiums ist es, die Kandidatinnen und Kandidaten zu befähigen, in ihrem Heimspital eine hepatologische Klinik mit Studien für Leberpatienten einzurichten. Zu diesem Zweck sieht das Programm eine Teilnahme an Projekten der klinischen Forschung (Diskussion von klinischen Fällen, GCP Training, Erstellung von Patienteninformationen und Einverständniserklärungen, Ethiskeingaben, Management von klinischen Studien) vor. Es gibt auch eine Interaktion mit dem klinischen Leber-Team auf dem Novartis Campus in Basel. Kandidatinnen und Kandidaten erhalten durch die Firma Novartis die Visumskosten, Unterkunft und Lebenshaltung, das Zentrum Verbrauchsmaterial, Administrations- und IT-Kosten in Zusammenhang mit dem Aufenthalt der Gäste finanziert. Im Berichtsjahr war Prof. Dr. med. Dr. phil. nat. Hwi Young Kim aus Korea während zwei Monaten unser Gast in Bern. Prof. Hwi Young Kim, Hepatologe am Ewha Womans University College of Medicine in Seoul, Südkorea, beschäftigte sich während seines Aufenthalts in Bern vor allem mit klinischen Projekten zum Management von Leberkrankheiten. Ausserdem tauschte er sich mit einem klinischen Team der Firma Novartis über neue Therapiemethoden aus.

### **CAS/DAS Lehrgänge in Hepatologie**

Infolge der Pandemie konnten im Berichtsjahr weder *Certificates of Advanced Studies in Hepatology*, Universität Bern (CAS HEP Unibe), noch *Diplomas of Advanced Studies in Hepatology*, Universität Bern (DAS HEP Unibe) abgeschlossen werden. Dr. med. Blanca Norero und Dr. med. Mirjam Kolev werden 2021 den CAS und DAS in Hepatologie absolvieren.

In der Hepatologischen **Poliklinik des Bauchzentrums** stellten sich im Jahr 2020 **7'205 Patientinnen und Patienten** vor. Es wurden 2'959 Ultraschall- und Doppleruntersuchungen, 128 Kontrastmittelverstärkte Ultraschalluntersuchungen, 1'087 HCC Screenings, 2'748 Fibroscan-Untersuchungen, 95 Aszitespunktionen, 130 transkutane und 44 ultraschallgesteuerte Leberbiopsien, 34 TIPS sowie 69 transjuguläre Leberbiopsien/Lebervenendruckmessungen, durchgeführt.

Die im Pandemiejahr durchgeführten drei **Hepatologie-Symposien** widmeten sich aktuellen Themen aus der hepatologischen Praxis:

#### *Hepatologie Symposium NASH (20.2.20)*

- Prof. Elisabetta Bugianesi, Medical Science Dept., University of Turin, I
- Prof. Jérôme Boursier, University Hospital Center, Angers, F

#### *Hepatologie Symposium Genetic Liver Diseases (10.9.20)*

- Prof. Manisha Balwani, Dept. of Genetics and Genomic Sciences, Icahn School of Medicine, Mt Sinai, New York City, USA
- Dr. Pavel Strnad, Dept. of Gastroenterology and Hepatology, University Hospital Aachen, D

#### *Hepatologie Symposium Imaging and Hepatocellular Carcinoma (5.11.20)*

- Dr. Matteo Renzulli, Radiology Dept., S. Orsola Malpighi University Hospital, Bologna, I
- Dr. Maria Reig, BCCLC Hospital Clinic of Barcelona, E

Der 7. **Lebertreff** fand am 3. November 2020 statt. Unter der Leitung von Prof. Dr. Dr. Nasser Semmo, UVCM Hepatologie, Dr. Guido Stirnimann, UVCM Hepatologie und PD Dr. Gilles Wandeler, Infektiologie Inselspital, erhielten niedergelassene Ärztinnen und Ärzte die Möglichkeit, ihre schwierigen Fälle mit den Hepatologen des Inselspitals zu diskutieren.

Der **HCC Day** konnte wegen der Corona Pandemie nicht stattfinden.

Am 30. September 2020 referierte **Dr. Eric Fell**, von der Universität Strasbourg (Institute of image-guided surgery (IHU) and IRCAD) zum Thema: *A biotech overview on regenerative medicine and disease: A multidisciplinary journey.*

Frau **Patcharamon Seubnooch** gab am 30. Juni einen Zwischenbericht über ihre Dissertation *Topological Metabolomics Imaging of Non-Alcoholic Fatty Liver Disease*, die sie unter der Leitung von Prof. Dufour an der UVCM Hepatologie macht.

#### **Masterabschlüsse in Medizin 2020**

Valerie Jasmin Will: *Current treatment options for refractory ascites in liver cirrhosis – a systematic review.*  
Hug Marcel Oliver Reiner: *Nivolumab for Hepatocellular Carcinoma*

#### **Dissertation Medizin 2020**

Margini Christina: *Prognostic Significance of Controlled Attenuation Parameter in Patients with Compensated Advanced Chronic Liver Disease.*

#### **Spenden**

Von Freundinnen und Freunden der Stiftung gingen 2020 wiederum grosszügige Spenden auf das Stiftungskonto ein. Herzlichen Dank!

Details der Veranstaltungen, Finanzen, Aktivitäten und Publikationen der UVCM Hepatologie finden Sie in den Anhängen 1 bis 4.



Bern, 31.12.2020/mo

#### **Beilagen:**

- Anhang 1: Beiträge an nationalen und internationalen Veranstaltungen
- Anhang 2: Drittmittel UVCM Hepatologie
- Anhang 3: Klinische Studien UVCM Hepatologie
- Anhang 4: Publikationen UVCM Hepatologie



## Anhang 1: Beiträge an nationalen und internationalen Veranstaltungen

### Prof. Dr. med. Jean-François Dufour

- Die gelbe OMA: NZZ Interview mit Stephanie Lahrtz über Leberkrankheiten. 27.01.20, Bern.
- 16. Berner Fortbildungskurs Klinische Immunologie und Rheumatologie. Abschiedssymposium Prof. Dr. med. Peter M. Villiger: Aktive Hepatitis und Immunosuppression. 03.07.20, Bern.
- Challenger. EASL Digital ILC Congress. Interactive Session on General hepatology up-date: Landmark papers in 2019. 29.08.20, virtuell.
- Joint Meeting SSM-SSI-SSHH 2020: Hepatocellular carcinoma surveillance in patients treated for viral hepatitis: who should we screen? 03.09.20, Geneva.
- UEG Week - Life Symposium COVID-19 and HPB: Presentation COVID-19 Impact on liver transplantation and liver cirrhosis. 12.10.20, virtuell.
- UEG Week - Clinical aspect of NAFLD session: Chair function. 12.10.20, virtuell.
- UEG Week - Life Symposium Fatty liver disease: Presentation What's new in 2020? Treatment of NASH: What is in the pipeline? 13.10.20, virtuell.
- LITMUS Steering Committee Meeting. 21.-22.10.20, virtuell.
- Quartals-Fortbildung Universitätsklinik für Rheumatologie und Klinische Immunologie (Michael Seitz): Präsentation Autoimmunhepatitis. 22.10.20, Bern.
- 6th Paris NASH Meeting/Institut Pasteur: Member of the Scientific programme (no presentation). 22-23.10.20, virtuell.
- Intercept DACH Steering Committee Meeting NASH. 20.10.20, virtuell.
- Liver intervention meeting: Presentation BCLC-B hepatocellular carcinoma: does one class fit for all? 10.20, virtuell.
- AASLD Liver Meeting Boston - Session Parallel 7: NAFLD and NASH: Prognostic and Diagnostic Methods: Presentation Noninvasive assessments to identify patients with advanced fibrosis due to NASH: Screened population from the regenerate trial. 14.11.20, virtuell.
- AASLD Liver Meeting Boston - Session Parallel 9: NAFLD and NASH: Therapeutics: Presentation Evaluation of obeticholic acid efficacy in patients with NASH who were monitored using noninvasive tests: a post hoc analysis of the regenerate trial. 15.11.20, virtuell.
- AASLD Liver Meeting Boston - Session Parallel 16: Hepatobiliary Neoplasia: Experimental and Novel Diagnostic/Imaging: Presentation Molecular and mutational landscape of hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH). 15.11.20, virtuell.
- Swiss Oncology & Hematology Congress 2020, Digital Industry Symposium: Presentation HCC - Things to consider in a fast moving treatment landscape: The Hepatologist's View. 21.11.20, Zürich, virtuell.
- HEP-CUP Post AASLD Liver Meeting 2020: Presentation NAFLD - Autoimmune Lebererkrankungen und Leberzirrhose. 11.20, virtual.
- Compact 7th HEP Preceptorship: Clinical case discussion with focus on HCC, 3.12.20, Bern, virtual.
- Clinical and Pathological Liver Symposium on Fatty Liver Disease, Fibrosis and HCC from the Perspective of Hepatologists and Pathologists: Presentation HCC from a hepatologists perspective. 10.12.20, virtuell.
- AstraZeneca - National Liver Cancer Advisory Board HCC (Benjamin Peschke). 24.11.20, virtuell.

### Prof Dr. med Dr. phil. nat. Annalisa Berzigotti

#### *Organisation von Meetings*

- Ultrasound and Elastography Course- fourth edition. Spanish Association for the Study of the liver (AEEH). Course Directors: A. Berzigotti, C. Garre, 14.-15.02.20, Madrid.
- Digital Symposium Hepatology 2020: Non-invasive diagnosis of Hepatocellular Carcinoma. Invited Speakers: Dr. Matteo Renzulli, Radiology Dept., University Hospital Bologna; Dr. Maria Reig, Hepatology, BCLC, Hospital Clinic, Barcelona, Spain. 05.11.20, UVCN Hepatologie, Bern.
- Seminar: Understanding the PI3King of Vascular Malformations. Given by Dr. Mariona Graupera, Dr. Mariona Graupera, IDIBELL, Barcelona. 03.11.20, virtuell.

#### *Einladung zu Vorträgen an inländischen und internationalen Meetings*

- Gastroenterology Bible Class: Presentation Decompensation and ascites in cirrhosis. 17.06.20, Inselspital UVCM, Bern.
- HepCup on Digital ILC 2020: Presentation Cirrhosis and its complications. 09.09.20, virtuell.
- Ipertensione Portale: inquadramento clinico e metodi diagnostici non invasive. 15.10.20, Epatocentro Lugano.
- Clinical and Pathological Liver Symposium on Fatty Liver Disease, Fibrosis and HCC from the perspective of hepatologists and pathologists. Presentation Fibrosis from a hepatologists perspective. Organized by Dr. Matteo Montani, Bern. 10.12.20, virtuell.
- Máster en Hepatología: Utilidad de la elastografía esplénica- Problemas clínicos en Hepatología. Autonom University of Madrid, 02.07.20, virtuell.
- Asociación Peruana de Anestesia, Cirugía y Endoscopía Bariátrica (APACEB), Lima: Utilidad de la elastografía esplénica. 07.09.20, virtuell.
- Digestive Endoscopy Cluj 2020: Presentation Is HVPG reliable in NAFLD/NASH? Cluj-Napoca, Romania, 29.10.20. virtuell.
- Meet the Expert 40. The Liver Meeting Digital Experience, Annual Meeting of the American Association for the Study of the Liver (AASLD): Presentation Non-invasive assessment of clinically significant portal hypertension. 16.11.20, virtuell.

### **Prof Dr. med Dr. phil. nat. Jamie Bosch**

#### **Vorträge**

- Paris Hepatology Conference, Lunch Symposium (Chair): Management of Difficult Ascites: role of TIPS and alpha-pump. 13.-14.01.20, Paris.
- Master Biomedicine, University of Bern. Lecture: Pathophysiology of portal hypertension. 12.02.20, Bern.
- Meeting of the Asociación Española para Estudio del Hígado. Special Address, Simposio Jóvenes Investigadores, 13.-15.02.20, Madrid.
- Master in Hepatology, University of Alcalá and Autonomous University of Madrid. Lecture: Estatinas en cirrosis: ¿listas para su uso en práctica clínica, 25.06.20, Madrid.
- The Digital International Liver Congress. Presidential Welcome Message: Hepatology Faces New Challenges. 20.08.20, virtuell.
- Actelion-Jansen PoPH. Lecture: From portal hypertension to Porto-Pulmonary Hypertension (PoPH). 27.08.20, Bern.
- 6th Adriatic Liver Forum-digital conference (dALF2020). Cirrhosis and portal hypertension: from guidelines to individualized approach. Lecture: Primary Prevention of Variceal Bleeding and Decompensation. 25.09.20, virtuell.
- Ticino Hepatology Forum. Lecture: New concepts in the treatment of portal hypertension. 16.10.20, HepatoCentro Lugano.
- European Respiratory Society International Congress Virtual 2020. Lecture: Personal highlights about pulmonary hypertension. 11.20, virtuell.
- Asociación Española para Estudio del Hígado-Spain Association for the Study of the Liver: Discusión Presentaciones sobre Cirrosis en el AASLD Digital Liver Meeting. 27.11.20, virtuell.
- Fortbildung Pneumologie/Thoraxchirurgie. Lecture: From portal hypertension (PH) to Porto-Pulmonary Hypertension. 19.11.20, Inselspital Bern.
- Frontiers in Liver Disease. Lecture: Optimal management of portal hypertension: Beyond Beta-Blockers. 17.11.20.
- Compact - HEP Preceptorship Virtual Meeting. What is challenging in the management of chronic liver diseases in 2020? Moderation. 03.12.20, virtuell.
- Emirates Association of Gastroenterology and Hepatology. Porto-pulmonary Hypertension Conference. Lecture: Porto-pulmonary hypertension from hepatology perspective. 08.12.20, virtuell.
- Clinical and Pathological Liver Symposium on Fatty liver disease, fibrosis and HCC from the perspective of hepatologists and pathologists: Virtual workshop clinical and pathological cases. 10.12.20, virtuell.

#### **Präsentationen in Meetings**

- Asociación Española para el Estudio del Hígado (AEEH). General Session 4: Factores predictores de supervivencia en la hemorragia variceal aguda de bajo riesgo en pacientes en profilaxis secundaria con betabloqueantes y/o ligadura endoscópica. Mandorfer, M, Hernandez-Gea V, Procopet B,....La Mura V, Bosch J, Garcia-Pagán JC. 12.-14.02.20, Madrid.

- Asociación Española para el Estudio del Hígado (AEEH). General Session 4: Novel use of a lineage reporter mouse for in vivo tracing of hepatocyte-derived extracellular vesicles in experimental liver disease. Blazquez-López E, Royo F, Vázquez-Ogando E, ... Bosch J, Bañares R, Gracia-Sancho J, Falcón-Pérez JM, Vaquero J. 12.-14.02.20, Madrid.
- Asociación Española para el Estudio del Hígado (AEEH). General Session 6: Biofísica del sinusoido hepático: la rigidez de la matriz extracelular modula el fenotipo de las células hepáticas en la cirrosis. Ortega-Ribera M, Guixe-Muntet S, Wang C, Selicean S, Roca-Cusachs P, Dufour JF, Bosch J, Berzigotti A, Gracia-Sancho J. 12.-14.02.20, Madrid.
- Asociación Española para el Estudio del Hígado (AEEH). Poster #9: El agonista pan-PAR Lanifibranor mejora la hipertensión portal y la fibrosis hepática en un modelo experimental de enfermedad hepática crónica avanzada. Aristu-Zabala P, Boyer-Díaz Z, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. 12.-14.02.20, Madrid.
- Asociación Española para el Estudio del Hígado (AEEH). Poster #45: Hypercoagulable state of patients with cirrosis does not play a major role in the development of portal vein thrombosis. Turon F, Baiges A, Cerda E, Garcia-Criado MA, Gilabert R, Bru C, Berzigotti A, Nuñez I, Orts L, Reverter JC, Blasi A, Hernandez-Gea V, Lisman T, Garcia JC. 12.-14.02.20, Madrid.
- Asociación Española para el Estudio del Hígado (AEEH). Poster #42: Influencia de las infecciones bacterianas en el riesgo de descompensación y en la supervivencia de la cirrosis compensada con hipertensión portal clínicamente significativa. Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, ... Torres F, Bosch J. 12.-14.02.20, Madrid.
- Asociación Española para el Estudio del Hígado (AEEH). Poster #43: TIPS precoz en el tratamiento de la hemorragia digestiva por varices esofágicas en pacientes de alto riesgo. Meta-análisis de datos individuales. Nicoara-Farcau O, Angrisani D, Monescillo A, Han G, Lu Y, Fan D, Torres F, Bosch J, Hernandez-Gea V, Garcia-Pagan JC. 12.-14.02.20, Madrid.
- The Digital Liver Meeting, AASLD. A Machine Learning Model Based on Liver Histology Predicts the Hepatic Venous Pressure Gradient in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis. Jaime Bosch, S A. Harrison, M F. Abdelmalek, M L. Schiffman, D C. Rockey, D Juyal Z Shantis, H Pokkalla, C Shukla, OM. Carrasco-Zevallos, M Resnick, M Montalto, A Beck, I Wapinski, C Jia, C Chung, R P. Myers, Z Goodman, N Afdhal, A J. Sanyal10. 13.-16.11.20, virtuell.
- The Digital Liver Meeting, AASLD. Oral Presentation: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. A J. Sanyal, QM. Anstee, M Trauner, E J. Lawitz, M F. Abdelmalek, D Ding, L Han, C Jia, M Camargo, K Kersey, R P. Myers, V Wai-Sun Wong, T Okanoue, M Romero-Gomez, A J. Muir, N H. Afdhal, J Bosch, Z Goodman, S A. Harrison, Z M. Younossi. 13.-16.11.20, virtuell.

## Anhang 2: Drittmittel UVCM Hepatologie

		Von	bis
<b>SNF Kredite</b>			
J.-F. Dufour	310030_185219/1 Kredit 18-556	01.04.2019	31.03.2023
A. Berzigotti	Inhibition of stiffness derived mol axis Kredit 19-012	01.01.2019	31.10.2022
<b>Ueberige Drittmittel</b>			
Universität Bern			
J.-F. Dufour	CCI779 Kredit 33-626	Diverse	unbefristet
J.-F. Dufour	LITMUS (EU Grant) Kredit 38-664	01.11.2017	31.10.2023
J.-F. Dufour	Roche Schweiz Kredit 38-978 HCC Kohortensponsoring	01.05.2019	unbefristet
N. Semmo	CAS/DAS Hepatology Studiengang Kredit 39-094	01.01.2018	unbefristet
J.-F. Dufour	Innosuisse Kredit 39-473	01.07.2019	30.06.2021
A. Berzigotti	CEUS NIH Kredit 39-664	01.01.2019	31.12.2021
J. Gracia Sancho	Novartis Stiftung Kredit 39-569	16.11.2018	unbefristet
J. Gracia Sancho	Fondation Suisse contre le cancer du foie Kredit 39-569	16.11.2018	unbefristet
J. Gracia Sancho	EASL PhD Fellowship (S. Selicean) Kredit 39-486	01.09.2019	31.08.2022
<b>Inselspital</b>			
N. Semmo	W. und G. Siegenthaler Stiftung Immunopathogenesis of hepatitis C virus infection CD4+T cell failure in chronic HCV infection		
J.-F. Dufour	Inselspital Guest Professorship		
J.-F. Dufour	Novartis Hepatology Training Fellowship Ausbildung		
J.-F. Dufour	Bayer AG, HCC und HepC Kohortensponsoring		
A. Berzigotti	Krebsforschung Schweiz	01.06.2017	31.05.2020
A. Berzigotti	BCPM	01.09.2019	30.09.2020
A. De Gottardi	Sequana Automatische Entfernung überschüssiger Peritonealflüssigkeit in die Harnblase bei Patienten mit Zirrhose und mit persistentem refraktärem Aszites		
N. Semmo	Swiss Hepatitis C Cohort Study Foundation		

## Anhang 3: Klinische Studien UVCM Hepatologie

### Leberkrebs

- **ARQ 197-A-U303** (METIV-HCC): A phase 3, randomized, double-blind study of Tivantinib (ARQ197) in subjects with MET diagnostic-high inoperable HCC treated with one prior systemic therapy.
- **LILLY (REACH 2) I4T-MC-JVDE**: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib.
- **BMS HCC CA209-459**: Nivolumab, Phase 3: A Randomized, Multi-Center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma.
- **HCC Cohort**: Kohortenstudie von Patienten mit Hepatozellulärem Karzinom.
- **BLU-554-1101**: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BLU554 in Patients with HCC.
- **Hepcasus**: Genome studies of hepatocellular carcinoma developed in hepatitis C patients with sustained virological response.
- **DAA AND CANCER**: Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of intra- and extrahepatic Malignancies in Patients with Chronic Hepatitis C.
- **AxI S**: sAxl as Diagnostic Biomarker of Steatosis- and Hepatitis Virus-Induced Hepatocellular Carcinoma.
- **CEUS**: Kontrastmittel-verstärkter Ultraschall zur Beurteilung von fokalen Leberläsionen in Patienten mit Zirrhose oder anderen Risikofaktoren für ein Hepatocelluläres Carcinom (HCC).
- **MK3475-937**: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937).
- **Cosmic(Exelixis) (OASIS)**: XL184-312, A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in patients with advanced HCC who Have Not Received Previous Systemic Anticancer Therapy.
- **Discovery of Biomarker Predictors of Response and Resistance to Checkpoint inhibitors in Advanced HCC**. Multicentre study.
- **DAA on Occurrence and Recurrence of Hep. Malignancies**.

### Virale Hepatitis

- **GS-US-337-0124**: A phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination Ribavirin Administered in Subjects Infected with Chronic HCV who Have Advanced Liver Disease or are Post-Liver Transplant.
- Investigation of the **Endocannabinoid System in Hepatitis C Infection**.
- **Abbvie M14-423**: A Study to Evaluate Long-term Outcomes Following Treatment with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II).
- **SCCS - Schweizerische Hepatitis C Kohortenstudie mit Hepatitis C Virus Infizierten**: Lack of Physical Activity as a Risk Factor for HCC in Patients with chronic Hepatitis C, Analyse von Blutproben, gesammelt im Rahmen der SCCS-Kohortenstudie.
- **Biostest**: A Retrospective Data Collection to Increase the Knowledgebase of Post-Transplant Treatment with the Human Hepatitis B Immunoglobulin Zutectra or Hepatect CP in Liver Transplanted Patients.
- **Bern-Lugano-HCV-Study**: Retrospective analysis of the outcomes of HCV infected individuals in the hospital setting in Switzerland.
- **Eiger**: A phase 3, matrix design, partially double-blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg peg IFN Alfa-2a for 48 Weeks Compared with Peg IFN Alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR).
- **Hematite**: Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment Naïve Patients Suffering from Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets.
- **HCV Kohorte**: SCCS Swiss Hepatitis C Cohort Study.

- **HBV Kohorte:** Swiss Hepatitis B Cohort Study. SASL 37.
- **CMV T-Track.**
- **AIDAA:** Effect of HCV clearance by DAA on evolution of AIDS, or: DAA on evolution of AIDS (Gilead), SASL 42.
- **DAA AND CANCER:** Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of intra- and extrahepatic Malignancies in Patients with Chronic Hepatitis C.

#### *Metabolische Leberkrankheiten*

- **GS-US-416-2124** A Phase 2, double blind, randomized study evaluating the safety, tolerability and efficacy of GS-4997 in combination with Prednisolon versus Prednisolon alone in subjects with severe alcoholic hepatitis.
- **Genfit GFT505 in NASH** Phase 3: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of elafibranor in patients with non-alcoholic steatohepatitis and Fibrosis (Emricasan).
- **NASH EU FLIP Cohort:** EU-FLIP Cohort of patients with non-alcoholic steatohepatitis.
- **SASL 34** Treatment of non-alcoholic steatohepatitis (NASH) patients with vitamin D. A randomized, double blind, placebo-controlled multicentre phase II trial in patients with fatty liver disease.
- **Intercept 747-303 NASH (REGENERATE):** A Phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of obeticholic acid in subjects with nonalcoholic steatohepatitis.
- **Native:** A Randomized, double-blind, placebo-controlled, multicenter dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with non-alcoholic steatohepatitis.
- **Litmus** The European NAFLD Registry LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis).
- **MACK3 & CirrhoNASH Score Validation.**
- **NOVARTIS NASH CLJC242A2201J TANDEM:** A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis.
- **NUT-3/NAS** (Falk GmbH) Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH).
- **Litmus sub-study imaging:** Litmus Sub-Study Imaging: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment and Validation of Imaging Modality Performance across the NAFLD Spectrum in a Prospectively Recruited Cohort.
- **Topological Metabolomics Imaging of Non-Alcoholic Fatty Liver Disease.**
- **CD8 T Cells Cause Liver Damage in Steatohepatitis which is Aggravated by anti PD-1 Immunotherapy.**
- **Fimadia:** Non-Invasive Findings of Fibrotic MAFLD Patients in Diabetes Outpatient Clinic.

#### *Zirrhose*

- **INFECIR-2:** Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality SCNTP880.
- Genotypic and Phenotypic **Characterization of Albumin in Cirrhotic Patients.**
- **The added value of CAP** in advanced chronic liver disease.
- **Predicting Acute-on-Chronic liver failure in cirrhosis.**
- **NABEL** Zirrhosen-Datenbank (Kanada und Bern).
- **Alfafump Nutrition:** Untersuchung des Einflusses von Ernährungsfaktoren auf das Outcome von Patienten mit einer alfa (automated low-flow ascites) Pumpe.
- **AURORA** (Tobira) Allergan: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (TOBIRA).
- **Bakterielle Infektionen in Patienten mit Zirrhose:** Einfluss eines antibiotischen Ueberwachungsprotokolls auf Hospitalisationszeit und Sterblichkeit.
- **Cirrhosis Regression:** Predictive Factors of Cirrhosis Regression in Patients with Advanced Chronic Liver Disease.
- **Combination of Non-Invasive Tests** in Chronic Liver Disease to Improve a Stage-Targeted Risk Stratification and Outcome Prediction.
- **Trust:** A phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects with Acute-on-Chronic Liver Failure.

- **Elasto Surgery Study:** Prognostic Role of Portal Hypertension Assessed by Non-Invasive Methods to Stratify Surgical Risk in Compensated Advanced Chronic Liver Disease Patients Undergoing Elective Abdominal Extrahepatic Surgery.

#### Vaskuläre Lebererkrankung

- **SASL 35:** Swiss Liver Venous Thrombosis Study: A multicenter prospective observational cohort study.
- **Valdig Konsortium zur Förderung des Studiums von vaskulären Lebererkrankungen.**

#### Auto-immune Krankheiten

- **Intercept 747-302 Cobalt:** A Phase 3b, double-blind, randomized, placebo-controlled, multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with primary biliary cirrhosis.
- **Novartis CVAY736B2201** A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER).
- **SASL 38:** Swiss Registry on Autoimmune Hepatitis.
- **SASL 39:** Swiss Registry on Primary Biliary Cholangitis.
- **SASL 40:** Swiss Cohort on Primary Sclerosing Cholangitis.
- **IgG4 Kohorte:** Swiss IgG4-Related Hepato-Biliary Disease Cohort Study (SASL43).
- **NUC-5-PSC (Navitas)** Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis.
- **GS-US-428-4194 PSC:** A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis.
- **Intercept 747-401:** A phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment.
- Retrospective Analysis of Patients with **Primary Biliary Cholangitis** and Prevalence of other Autoimmune Diseases with a Focus on Prognostic Impact in the Presence of **Associated Sjögren's Syndrome**.

#### Andere Lebererkrankungen

- Investigation of liver involvement in patients with **alpha1-Antitrypsin Deficiency**.
- Retrospective Analysis of Patients with **Sarcoidosis with Hepatic Manifestation**.
- A Pilot Study of Renal Perfusion Evaluation Using Contrast Echography in Hepatorenal Syndrome on Terlipressin Treatment.
- **SarsCov-2 LTx:** Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) Infection: Epidemiology of an International Liver Transplant Cohort.
- **SarsCov-2 LTx:** Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) Infection: Serologic Response in Liver Transplanted Patients.

#### Medikamenten-induzierte Lebererkrankungen

- **Pro-Euro DILI Registry:** Creation of a Multicentre and Multidisciplinary European Registry of Prospective Drug-Induced Liver Injury Cases (Pro-Euro-DILI).
- **T-cell response in DILI** (Amendment to DILI).

#### Gesundheitsmanagement

- **Constans:** A multi-center, multinational survey of NAFLD-related hospital visits: prevalence, severity, patterns of clinical practice and health-care costs. The CONSTANS Study (Consultations for steatohepatitis).
- **Mythen:** Hep C and microbiota (Abbvie): Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir plus Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 to 6 (post-marketing).
- **Untersuchung des Einflusses von Ernährungsfaktoren auf das Outcome von Patienten mit einer alfa (automated low-flow ascites) Pumpe.**

## Anhang 5: Publikationen UVCM Hepatologie

### Prof. Dr. med. Jean-François Dufour

1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratiu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol.* 2020 Jul;73(1):202-209.
2. Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz MR. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. *Gut.* 2020 Apr;69(4):764-780.
3. Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. *Gut.* 2020 Oct;69(10):1877-1884.
4. Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Höglström S, Richardson B, Munoz C, Sigurðardóttir S, Coulibaly A, Milan M, Bautista F, Leung NWY, Mooney V, Obekpa S, Bech E, Polavarapu N, Hamed AE, Radiani T, Purwanto E, Bright B, Ali M, Dovia CK, McColaugh L, Koulla Y, Dufour JF, Soliman R, Eslam M. Redefining fatty liver disease: an international patient perspective. *Lancet Gastroenterol Hepatol.* 2021 Jan;6(1):73-79.
5. Schwacha-Eipper B, Minciuna I, Banz V, Dufour JF. Immunotherapy as a Downstaging Therapy for Liver Transplantation. *Hepatology.* 2020 Oct;72(4):1488-1490.
6. Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. *Nat Rev Gastroenterol Hepatol.* 2020 Oct 22.
7. Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratiu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>>☆</sup>. *J Hepatol.* 2020 Sep;73(3):505-515.</sup>
8. Bechetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, Dahlqvist G, Ciccarelli O, Morelli MC, Fraga M, Svegliati-Baroni G, van Vlierberghe H, Coenraad MJ, Romero MC, de Gottardi A, Toniutto P, Del Prete L, Abbati C, Samuel D, Pirenne J, Nevens F, Dufour JF; COVID-LT group. COVID-19 in an international European liver transplant recipient cohort. *Gut.* 2020 Oct;69(10):1832-1840.
9. Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, Weiss KH, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley TWM, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber RE, Canbay A, Link A, Valenti L, Grove JL, Aithal GP, Marquardt JU, Fateen W, Zopf S, Dufour JF, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, Morgan MY. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. *Hepatology.* 2020 Jul;72(1):88-102.
10. Sobolewski C, Abegg D, Berthou F, Dolicka D, Calo N, Sempoux C, Fournier M, Maeder C, Ay AS, Clavien PA, Humar B, Dufour JF, Adibekian A, Foti M. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. *Gut.* 2020 Oct;69(10):1841-1854.
11. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int.* 2020 May;40(5):1151-1158.
12. Bechetti C, Dirchwolf M, Banz V, Dufour JF. Medical management of metabolic and cardiovascular complications after liver transplantation. *World J Gastroenterol.* 2020 May 14;26(18):2138-2154.
13. Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. *Gut.* 2020 Aug;69(8):1374-1376.
14. Guixé-Muntet S, Ortega-Ribera M, Wang C, Selicean S, Andreu I, Kechagias JZ, Fondevila C, Roca-Cusachs P, Dufour JF, Bosch J, Berzigotti A, Gracia-Sancho J. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. *JHEP Rep.* 2020 Jul 17;2(5):100145.
15. Kim HY, Dufour JF. Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma. *Clin Mol Hepatol.* 2020 Apr;26(2):238-239.
16. Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, Foti M, Nuoffer JM, St-Pierre MV, Dufour JF. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. *Cancers (Basel).* 2020 May 29;12(6):1407.
17. Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratiu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. *Contemp Clin Trials.* 2020 Nov;98:106175.
18. von Hessen L, Roumet M, Maurer MH, Lange N, Reeves H, Dufour JF, Radu IP. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. *Liver Int.* 2020 Dec 6.
19. Tang KT, Dufour JF, Chen PH, Hernaez R, Hutfless S. Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. *BMJ Open Gastroenterol.* 2020 Apr 15;7(1):e000349.
20. R Galle P, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. *Future Oncol.* 2020 Dec 14.
21. Linecker M, Frick L, Kron P, Limani P, Kambakamba P, Tschor C, Langiewicz M, Kachaylo E, Tian Y, Schneider MA, Ungethüm U, Calo N, Foti M, Dufour JF, Graf R, Humar B, Clavien PA. Exercise Improves Outcomes of Surgery on Fatty Liver in Mice: A Novel Effect Mediated by the AMPK Pathway. *Ann Surg.* 2020 Feb;271(2):347-355.
22. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O; Swiss Hepatitis C Cohort Study. Very Low Hepatitis C Viral Loads in Treatment-naïve Persons: Do They Compromise Hepatitis C Virus Antigen Testing? *Clin Infect Dis.* 2020 Feb 3;70(4):653-659.

23. Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. *Cancers (Basel)*. 2020 Dec 18;12(12):3830.

**Prof. Dr. med. Dr. phil. nat. Annalisa Berzigotti**

1. Rodrigues SG, Abraldes JG, Tsochatzis E, Bosch J, Berzigotti A. Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. *Liver Int*. 2020 Dec 14.
2. Obmann VC, Berzigotti A, Catucci D, Ebner L, Grani C, Heverhagen JT, Christe A, Huber AT. T1 mapping of the liver and the spleen in patients with liver fibrosis-does normalization to the blood pool increase the predictive value? *Eur Radiol*. 2020 Dec 11.
3. Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, Procopet B, Schwabl P, Ferlitsch A, Semmler G, Berzigotti A, Tschoatzis E, Bureau C, Reiberger T, Bosch J, Abraldes JG, Genescà J. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. *Am J Gastroenterol*. 2020 Oct 8.
4. Wan T, Köhn N, Kröll D, Berzigotti A. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. *Obes Surg*. 2020 Sep 22.
5. Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. *Dig Liver Dis*. 2020 Sep;52(9):958-965.
6. Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, Chammas MC, Chaubal N, Choi BI, Clevert DA, Cui X, Dong Y, D'Onofrio M, Fowlkes JB, Gilja OH, Huang P, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lee WJ, Lee JY, Liang P, Lim A, Lyshchik A, Meloni MF, Correas JM, Minami Y, Moriyasu F, Nicolau C, Piscaglia F, Saftoiu A, Sidhu PS, Sporea I, Torzilli G, Xie X, Zheng R. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. *Ultrasound Med Biol*. 2020 Oct;46(10):2579-2604.
7. Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, Chammas MC, Chaubal N, Choi BI, Clevert DA, Cui X, Dong Y, D'Onofrio M, Fowlkes JB, Gilja OH, Huang P, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lee WJ, Lee JY, Liang P, Lim A, Lyshchik A, Meloni MF, Correas JM, Minami Y, Moriyasu F, Nicolau C, Piscaglia F, Saftoiu A, Sidhu PS, Sporea I, Torzilli G, Xie X, Zheng R. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. *Ultraschall Med*. 2020 Oct;41(5):562-585. English.
8. Guixé-Muntet S, Ortega-Ribera M, Wang C, Selicean S, Andreu I, Kechagia JZ, Fondevila C, Roca-Cusachs P, Dufour JF, Bosch J, Berzigotti A, Gracia-Sancho J. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. *JHEP Rep*. 2020 Jul 17;2(5):100145.
9. La Mura V, Garcia-Guix M, Berzigotti A, Abraldes JG, García-Pagán JC, Villanueva C, Bosch J. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. *Hepatology*. 2020 Oct;72(4):1353-1365.
10. Petta S, Sebastiani G, Vigàò M, Ampuero J, Wai-Sun Wong V, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, Grottes MD, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxì A, de Ledinghen V. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease. *Clin Gastroenterol Hepatol*. 2020 Jul 1:S1542-3565(20)30908-3.
11. Will V, Rodrigues SG, Stirnemann G, Gottardi A, Bosch J, Berzigotti A. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. *United European Gastroenterol J*. 2020 Oct;8(8):961-969.
12. Berger A, Ravaioli F, Farcau O, Festi D, Stefanescu H, Buisson F, Nahon P, Bureau C, Ganne-Carriè N, Berzigotti A, de Ledinghen V, Petta S, Calès P; multicenter groups VO-VCO, ANRS CO12 CIRVIR, M116m, and VEB6. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. *Clin Gastroenterol Hepatol*. 2020 Jun 17:S1542-3565(20)30833-8.
13. Piscaglia F, Stefanini F, Cantisani V, Sidhu PS, Barr R, Berzigotti A, Chammas MC, Correas JM, Dietrich CF, Feinstein S, Huang P, Jenssen C, Kono Y, Kudo M, Liang P, Lyshchik A, Nolsøe C, Xie X, Tovoli F. Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts. *Ultraschall Med*. 2020 Jun;41(3):228-236. English.
14. Mendoza Y, Cocciliello S, Murgia G, Chen T, Margini C, Sebastiani G, Berzigotti A. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. *Clin Gastroenterol Hepatol*. 2020 Dec;18(13):3017-3025.e6.
15. Thiele M, Hugger MB, Kim Y, Rautou PE, Elkrief L, Jansen C, Verlinden W, Allegretti G, Israelsen M, Stefanescu H, Piscaglia F, García-Pagán JC, Franque S, Berzigotti A, Castéra L, Jeong WK, Trebicka J, Krag A. 2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. *Liver Int*. 2020 Jun;40(6):1435-1446.
16. Praktikno M, Simón-Talero M, Rörmer J, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, Llop E, Maurer MH, Zippich A, Triolo M, Maleux G, Fialla AD, Dam C, Vidal-González J, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, López M, Jansen C, Chang J, Schierwagen R, Uschner F, Kukuk G, Meyer C, Thomas D, Wolter K, Strassburg CP, Laleman W, La Mura V, Ripoll C, Berzigotti A, Calleja JL, Tandon P, Hernandez-Gea V, Reiberger T, Albillas A, Tschoatzis EA, Krag A, Genescà J, Trebicka J; Baveno VI-SPSS group of the Baveno Cooperation. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. *J Hepatol*. 2020 Jun;72(6):1140-1150.
17. Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Schiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillas A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators(‡). Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. *J Hepatol*. 2020 May;72(5):885-895.
18. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnemann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int*. 2020 May;40(5):1151-1158.

19. Tandon P, Berzigotti A. Management of Lifestyle Factors in Individuals with Cirrhosis: A Pragmatic Review. *Semin Liver Dis.* 2020 Feb;40(1):20-28.
20. Hügel U, Delgado MG, Baumgartner I, Bosch J, Berzigotti A. Indikationen und Erfahrungen zur transjugulären intrahepatischen portosystemischen Shuntanlage (TIPS): Update 2019. *Swiss Medical Weekly.* 2020.
21. Obmann VC, Marx C, Hrycyk J, Berzigotti A, Ebner L, Mertineit N, Gräni C, Heverhagen JT, Christe A, Huber AT. Liver segmental volume and attenuation ratio (LSVAR) on portal venous CT scans improves the detection of clinically significant liver fibrosis compared to liver segmental volume ratio (LSVR). *Abdom Radiol (NY).* 2020 Nov 6.
22. Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N; Liver Forum NASH Cirrhosis Working Group. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. *Gastroenterology.* 2020 Aug;159(2):422-427.e1.
23. Mendoza YP, Murgia G, Gomes Rodrigues S, Delgado MG, Berzigotti A; (2020). Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications. In: *Liver Elastography* (S. 325-359). Cham: Springer International Publishing.

**Prof. Dr. med. Dr. phil. nat. Jaime Bosch**

1. Rodrigues SG, Abraldes JG, Tsochatzis E, Bosch J, Berzigotti A. Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. *Liver Int.* 2020 Dec 14.
2. Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. *J Hepatol.* 2020 Dec 2:S0168-8278(20)33832-0.
3. Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, Procopet B, Schwabl P, Ferlitsch A, Semmler G, Berzigotti A, Tsochatzis E, Bureau C, Reiberger T, Bosch J, Abraldes JG, Genescà J. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. *Am J Gastroenterol.* 2020 Oct 8.
4. La Mura V, Villanueva C, Abraldes JG, Bosch J. Reply. *Hepatology.* 2020 Oct;72(4):1494-1495.
5. Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, Casanova G, Bosch J, Lv Y, Thabut D, Fan D, Hernández-Gea V, García-Pagán JC; preemptive TIPS individual data metaanalysis, International Variceal Bleeding Study and Baveno Cooperation Study groups. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. *Gastroenterology.* 2020 Sep 24:S0016-5085(20)35207-0.
6. Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia- Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. *Nutrients.* 2020 Aug 28;12(9):2627.
7. Pietrosi G, Fernández-Iglesias A, Pampalone M, Ortega-Ribera M, Lozano JJ, García-Calderó H, Abad-Jordà L, Conaldi PG, Parolini O, Vizzini G, Luca A, Bosch J, Gracia-Sancho J. Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. *Liver Int.* 2020 Oct;40(10):2500-2514.
8. Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. *Dig Liver Dis.* 2020 Sep;52(9):958-965.
9. Guixé-Muntet S, Ortega-Ribera M, Wang C, Selicean S, Andreu I, Kechagia JZ, Fondevila C, Roca-Cusachs P, Dufour JF, Bosch J, Berzigotti A, Gracia-Sancho J. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. *JHEP Rep.* 2020 Jul 17;2(5):100145.
10. Trebicka J, Gu W, García-Pagán JC, Bosch J, Bañares R. Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why? *J Hepatol.* 2020 Oct;73(4):977-979.
11. La Mura V, García-Guix M, Berzigotti A, Abraldes JG, García-Pagán JC, Villanueva C, Bosch J. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. *Hepatology.* 2020 Oct;72(4):1353-1365.
12. Povero D, Yamashita H, Ren W, Subramanian MG, Myers RP, Eguchi A, Simonetto DA, Goodman ZD, Harrison SA, Sanyal AJ, Bosch J, Feldstein AE. Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. *Hepatol Commun.* 2020 Jul 3;4(9):1263-1278.
13. Will V, Rodrigues SG, Stirnemann G, Gottardi A, Bosch J, Berzigotti A. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. *United European Gastroenterol J.* 2020 Oct;8(8):961-969.
14. Trebicka J, Gu W, Ibáñez-Samaniego L, Hernández-Gea V, Pitarch C, Garcia E, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Silva-Junior G, Martinez J, Genescà J, Bureau C, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud L, Ferreira CN, Barcelo R, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sastrelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Weiss E, Catalina MV, Erasmus HP, Uschner FE, Schulz M, Brol MJ, Praktikno M, Chang J, Krag A, Nevens F, Calleja JL, Robic MA, Conejo I, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, Torres F, Pavesi M, García-Pagán JC, Jansen C, Bañares R; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. *J Hepatol.* 2020 Nov;73(5):1082-1091.
15. Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. *Gut.* 2020 May;69(5):953-962.
16. Hide D, Warren A, Fernández-Iglesias A, Maeso-Díaz R, Peralta C, Le Couteur DG, Bosch J, Cogger VC, Gracia-Sancho J. Ischemia/Reperfusion Injury in the Aged Liver: The Importance of the Sinusoidal Endothelium in Developing Therapeutic Strategies for the Elderly. *J Gerontol A Biol Sci Med Sci.* 2020 Jan 20;75(2):268-277.
17. Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Schiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ; IDN-6556-14 Investigators(‡). Randomized placebo-controlled trial of emricasan for non- alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. *J Hepatol.* 2020 May;72(5):885-895.
18. Turco L, Villanueva C, La Mura V, García-Pagán JC, Reiberger T, Genescà J, Groszmann RJ, Sharma BC, Merkel C, Bureau C, Alvarado E, Abraldes JG, Albillos A, Bañares R, Peck-Radosavljevic M, Augustin S, Sarin SK, Bosch J, García-Tsao G. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. *Clin Gastroenterol Hepatol.* 2020 Feb;18(2):313-327.e6.
19. Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. *JHEP Rep.* 2019 Dec 20;2(1):100063.

20. Bosch J. Small diameter shunts should lead to safe expansion of the use of TIPS. *J Hepatol*. 2021 Jan;74(1):230-234.
21. Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N; Liver Forum NASH Cirrhosis Working Group. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. *Gastroenterology*. 2020 Aug;159(2):422-427.e1.
22. Ruart M, Chavarria L, Campreciós G, Suárez-Herrera N, Montironi C, Guixé-Muntet S, Bosch J, Friedman SL, Garcia-Pagán JC, Hernández-Gea V. Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469]. *J Hepatol*. 2020 Sep;73(3):744.

#### **Prof. Dr. med. Dr. phil. nat. Nasser Semmo**

1. Mouillet B, Kolev M, Ebner L, Langer R, Gräni C, Obmann V, Maurer M, Semmo N, Christe A, Huber AT. Adult form of Langerhans cell histiocytosis with pulmonary and hepatic involvement mimicking malignancy in a patient with chronic hepatitis C infection. *Radiol Case Rep*. 2020 Dec 3;16(2):327-333.
2. Semmo N, Müllhaupt B, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Semela D. A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study. *PLoS One*. 2020 Nov 4;15(11):e0241267.
3. Roelens M, Bertisch B, Moradpour D, Cerny A, Semmo N, Schmid P, Müllhaupt B, Clerc O, Semela D, Junker C, Negro F, Keiser O; Swiss Hepatitis C Cohort Study. All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). *Open Forum Infect Dis*. 2020 Jul 25;7(8):ofaa308.
4. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int*. 2020 May;40(5):1151-1158.
5. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, Schmid P, Giudici F, Clerc O, Moriggia A, Roelens M, Marinucci F, Zehnder C, Moradpour D, Keiser O; Swiss Hepatitis C Cohort Study. Very Low Hepatitis C Viral Loads in Treatment-naïve Persons: Do They Compromise Hepatitis C Virus Antigen Testing? *Clin Infect Dis*. 2020 Feb 3;70(4):653-659.

#### **Dr. med. Guido Stirnimann**

1. Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. *Swiss Med Wkly*. 2020 Dec 5;150:w20364.
2. Terzioli Beretta-Piccoli B, Stirnimann G, Mertens J, Semela D, Zen Y, Mazzucchelli L, Voreck A, Kolbus N, Merlo E, Di Bartolomeo C, Messina P, Cerny A, Costantini S, Vergani D, Mieli-Vergani G; Swiss PBC Cohort Study Group. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. *J Autoimmun*. 2020 Nov 20:102578.
3. Vermathen P, Diserens G, Kroell D, Nett P, Stirnimann G, Wiest R. Determination of bile acids from human gallbladder by <sup>1</sup>H-MRS- Protocol optimization and estimation of reproducibility. *NMR Biomed*. 2020 Oct 28:e4432.
4. Will V, Rodrigues SG, Stirnimann G, Gottardi A, Bosch J, Berzigotti A. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. *United European Gastroenterol J*. 2020 Oct;8(8):961-969.
5. Zermatten MG, Fraga M, Moradpour D, Bertaggia Calderara D, Aliotta A, Stirnimann G, De Gottardi A, Alberio L. Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. *Hepatology*. 2020 Jun;71(6):2135-2148.
6. Kröll D, Müller AC, Nett PC, Wiest R, Maubach J, Stirnimann G, Candinas D, Borbely YM. Tailored access to the hepatobiliary system in post-bariatric patients: a tertiary care bariatric center experience. *Surg Endosc*. 2020 Dec;34(12):5469-5476.
7. Bertaggia Calderara D, Aliotta A, Zermatten MG, Kröll D, Stirnimann G, Alberio L. Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters. *Thromb Res*. 2020 Mar;187:91-102.
8. van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, Hirzel C, Khanna N, Weisser M, Garzoni C, Boggian K, Berger C, Nadal D, Koller M, Saccilotto R, Mueller NJ; Swiss Transplant Cohort Study. Burden and Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss Transplant Cohort Study. *Clin Infect Dis*. 2020 Oct 23;71(7):e159-e169.
9. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int*. 2020 May;40(5):1151-1158.
10. Tschopp J, L'Huillier AG, Mombelli M, Mueller NJ, Khanna N, Garzoni C, Meloni D, Papadimitriou-Olivgeris M, Neofytos D, Hirsch HH, Schuurmans MM, Müller T, Berney T, Steiger J, Pascual M, Manuel O, van Delden C; Swiss Transplant Cohort Study (STCS). First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. *Am J Transplant*. 2020 Oct;20(10):2876-2882.
11. Vu DL, Dayer JA, Masouridi-Levrat S, Combescure C, Boely E, Khanna N, Mueller NJ, Kleber M, Medinger M, Halter J, Passweg J, Müller AM, Schanz U, Chalandon Y, Neofytos D, van Delden C, Kaiser L; Swiss Transplant Cohort Study. Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. *Transpl Infect Dis*. 2020 Aug;22(4):e13289.
12. Muller YD, Vionnet J, Beyeler F, Eigenmann P, Caubet JC, Villard J, Berney T, Scherer K, Spertini F, Fricker MP, Lang C, Schmid-Grendelmeier P, Benden C, Roux Lombard P, Aubert V, Immer F, Pascual M, Harr T; Swiss Transplant Cohort Study. Management of allergy transfer upon solid organ transplantation. *Am J Transplant*. 2020 Mar;20(3):834-843.
13. Galle, Peter; Kudo, Masatoshi; Llovet, Josep M.; Finn, Richard; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Zagonel, Vittorina; Tomasek, Jiri; Philip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Wang, Chunxiao; Ogburn, Kenyon; Abada, Paolo B.; Widau, Ryan; Zhu, Andrew (2020). Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2. *Journal of hepatology*, 73(S1), S386-S387. Elsevier 10.1016/S0168-8278(20)31264-2

14. Costantini, Silvia; Cerny, Andreas; Stirnimann, Guido; Sinnreich, Magdalena Filipowicz; Mertens, Joachim C.; Semela, David; Baserga, Adriana; Bellentani, Stefano; Merlo, Elisabetta; Mieli-Vergani, Giorgina; Vergani, Diego; Terzioli, Benedetta (2020). Histological primary biliary cholangitis changes in patients with positive serology and normal alkaline phosphatase. *Journal of hepatology*, 73(S1), S461-S462. Elsevier 10.1016/S0168-8278(20)31406-9
15. Finn, Richard C; De Toni, Enrico N; Chung Cheung Yau, Thomas; Yen, Chia-Jui; Hsu, Chih-Hung; Chan, Stephen L; He, Aiwu Ruth; Galle, Peter; Trojan, Jörg; Stirnimann, Guido; Baron, Ari; Rivera, Mirelis Acosta; Goyal, Lipika; Wang, Chunxiao; Abada, Paolo; Widau, Ryan; Zhu, Andrew X (November 2020). Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort. In: SOHC 2020 - Swiss Oncology & Hematology Congress - 3rd; Online Conference. November 18 - 21, 2020.

#### **Dr. med. Susana Gomes Rodrigues**

1. Rodrigues SG, Abraldes JG, Tsochatzis E, Bosch J, Berzigotti A. Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. *Liver Int.* 2020 Dec 14.
2. Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, Procopet B, Schwabl P, Ferlitsch A, Semmler G, Berzigotti A, Tsochatzis E, Bureau C, Reiberger T, Bosch J, Abraldes JG, Genescà J. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. *Am J Gastroenterol.* 2020 Oct 8.
3. Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. *Dig Liver Dis.* 2020 Sep;52(9):958-965.
4. Will V, Rodrigues SG, Stirnimann G, Gottardi A, Bosch J, Berzigotti A. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. *United European Gastroenterol J.* 2020 Oct;8(8):961-969.
5. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int.* 2020 May;40(5):1151-1158.
6. Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. *JHEP Rep.* 2019 Dec 20;2(1):100063.
7. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int.* 2020 May;40(5):1151-1158.
8. Mendoza YP, Murgia G, Gomes Rodrigues S, Delgado MG, Berzigotti A; (2020). Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications. In: *Liver Elastography* (S. 325-359). Cham: Springer International Publishing.

#### **Dr. med. Pompilia Radu**

1. Sparchez Z, Mocan T, Radu P, Nenu I, Comsa M, Hajjar NA, Mois E, Bartos A, Kacso G, Sparchez M. Microwave ablation in the treatment of liver tumors. A better tool or simply more power? *Med Ultrason.* 2020 Nov 18;22(4):451-460.
2. Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. *Gut.* 2020 Aug;69(8):1374-1376.
3. Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. *Cancers (Basel).* 2020 Dec 18;12(12):3830.

#### **Dr. med. Maria Gabriela Delgado**

1. Piccinni R, Rodrigues SG, Montani M, Murgia G, Delgado MG, Casu S, Stirnimann G, Semmo N, De Gottardi A, Dufour JF, Berzigotti A. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. *Liver Int.* 2020 May;40(5):1151-1158.
2. Mendoza YP, Murgia G, Gomes Rodrigues S, Delgado MG, Berzigotti A; (2020). Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications. In: *Liver Elastography* (S. 325-359). Cham: Springer International Publishing.

#### **Dr. med. Yuly Mendoza**

1. Mendoza Y, Coccilillo S, Murgia G, Chen T, Margini C, Sebastiani G, Berzigotti A. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. *Clin Gastroenterol Hepatol.* 2020 Dec;18(13):3017-3025.e6.
2. Mendoza YP, Rodrigues SG, Bosch J, Berzigotti A. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. *Dig Liver Dis.* 2020 Sep;52(9):958-965.
3. Petta S, Sebastiani G, Vigàò M, Ampuero J, Wai-Sun Wong V, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, Grottes MD, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxi A, de Ledinghen V. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease. *Clin Gastroenterol Hepatol.* 2020 Jul 1:S1542-3565(20)30908-3.
4. Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. *JHEP Rep.* 2019 Dec 20;2(1):100063.
5. Mendoza YP, Murgia G, Gomes Rodrigues S, Delgado MG, Berzigotti A; (2020). Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications. In: *Liver Elastography* (S. 325-359). Cham: Springer International Publishing.

#### **Dr. med. Mirjam Kolev**

1. Mouillet B, Kolev M, Ebner L, Langer R, Gräni C, Obmann V, Maurer M, Semmo N, Christe A, Huber AT. Adult form of Langerhans cell histiocytosis with pulmonary and hepatic involvement mimicking malignancy in a patient with chronic hepatitis C infection. *Radiol Case Rep.* 2020 Dec 3;16(2):327-333.

**Dr. med. Chiara Beccetti**

1. Burra P, Beccetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. *JHEP Rep.* 2020 Oct;9(6):100192.
2. Beccetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, Dahlqvist G, Ciccarelli O, Morelli MC, Fraga M, Svegliati-Baroni G, van Vlierberghe H, Coenraad MJ, Romero MC, de Gottardi A, Toniutto P, Del Prete L, Abbati C, Samuel D, Pirenne J, Nevens F, Dufour JF; COVID-LT group. COVID-19 in an international European liver transplant recipient cohort. *Gut.* 2020 Oct;69(10):1832-1840.
3. Beccetti C, Dirchwolf M, Banz V, Dufour JF. Medical management of metabolic and cardiovascular complications after liver transplantation. *World J Gastroenterol.* 2020 May;16(18):2138-2154.

**Dr. phil. nat. Jordi Sergio Garcia Sancho**

1. Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. Pan-PPAR agonist lanifibrinor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. *J Hepatol.* 2020 Dec;S0168-8278(20)33832-0.
2. Pietrosi G, Fernández-Iglesias A, Pampalone M, Ortega-Ribera M, Lozano JJ, García-Calderó H, Abad-Jordà L, Conaldi PG, Parolini O, Vizzini G, Luca A, Bosch J, Gracia-Sancho J. Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats. *Liver Int.* 2020 Oct;40(10):2500-2514.
3. Azparren-Angulo M, Royo F, Gonzalez E, Liebana M, Brotons B, Berganza J, Goñi-de-Cerio F, Manicardi N, Abad-Jordà L, Gracia-Sancho J, Falcon-Perez JM. Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities. *Pharmacol Ther.* 2020 Sep;19:107683.
4. Guixé-Muntet S, Ortega-Ribera M, Wang C, Selicean S, Andreu I, Kechagia JZ, Fondevila C, Roca-Cusachs P, Dufour JF, Bosch J, Berzigotti A, Gracia-Sancho J. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. *JHEP Rep.* 2020 Jul;17(2):100145.
5. Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. *Nutrients.* 2020 Aug;28(12):2627.
6. Guixé-Muntet S, Zhu CP, Xie WF, Gracia-Sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. *Pharmacol Ther.* 2020 Nov; 215:107626.
7. Ortega-Ribera M, Hunt NJ, Gracia-Sancho J, Cogger VC. The Hepatic Sinusoid in Aging and Disease: Update and Advances From the 20th Liver Sinusoid Meeting. *Hepatol Commun.* 2020 Apr;27(4):1087-1098.
8. Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease - A practical approach for translational research. *J Hepatol.* 2020 Aug;73(2):423-440.
9. Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. *Gut.* 2020 May;69(5):953-962. Haute GV, Luft C, Antunes GL, Silveira JS, de Souza Basso B, da Costa MS, Levorse VGS, Kaiber DB, Donadio MVF, Gracia-Sancho J, de Oliveira JR. Anti- inflammatory effect of octyl gallate in alveolar macrophages cells and mice with acute lung injury. *J Cell Physiol.* 2020 Sep;235(9):6073-6084.
10. Martí-Rodrigo A, Alegre F, Moragrega ÁB, García-García F, Martí-Rodrigo P, Fernández-Iglesias A, Gracia-Sancho J, Apostolova N, Esplugues JV, Blas-García A. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. *Gut.* 2020 May;69(5):920-932.
11. Hide D, Warren A, Fernández-Iglesias A, Maeso-Díaz R, Peralta C, Le Couteur DG, Bosch J, Cogger VC, Gracia-Sancho J. Ischemia/Reperfusion Injury in the Aged Liver: The Importance of the Sinusoidal Endothelium in Developing Therapeutic Strategies for the Elderly. *J Gerontol A Biol Sci Med Sci.* 2020 Jan;75(2):268-277.

**Dr. phil. nat. Sergi Guixé-Muntet**

1. Guixé-Muntet S, Zhu CP, Xie WF, Gracia-Sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. *Pharmacol Ther.* 2020 Nov; 215:107626.
2. Guixé-Muntet S, Ortega-Ribera M, Wang C, Selicean S, Andreu I, Kechagia JZ, Fondevila C, Roca-Cusachs P, Dufour JF, Bosch J, Berzigotti A, Gracia-Sancho J. Nuclear deformation mediates liver cell mechanosensing in cirrhosis. *JHEP Rep.* 2020 Jul;17(2):100145.
3. Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, Foti M, Nuoffer JM, St-Pierre MV, Dufour JF. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. *Cancers (Basel).* 2020 May 29;12(6):1407.
4. Ruart M, Chavarria L, Campreciós G, Suárez-Herrera N, Montironi C, Guixé-Muntet S, Bosch J, Friedman SL, García-Pagán JC, Hernández-Gea V. Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469]. *J Hepatol.* 2020 Sep;73(3):744.
5. Hassan M, Moghadamrad S, Sorribas M, Muntet SG, Kellmann P, Trentesaux C, Fraudeau M, Nanni P, Wolski W, Keller I, Hapfelmeier S, Shroyer NF, Wiest R, Romagnolo B, De Gottardi A. Paneth cells promote angiogenesis and regulate portal hypertension in response to microbial signals. *J Hepatol.* 2020 Sep;73(3):628-639.

**Dr. phil. nat. Pavitra Kumar**

1. Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, Foti M, Nuoffer JM, St-Pierre MV, Dufour JF. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. *Cancers (Basel).* 2020 May 29;12(6):1407.

## **Besten Dank für Ihr Interesse an der Stiftung für Leberkrankheiten!**

Bank	Crédit Suisse AG, CH-3001 Bern
Post Account Bank:	30-3200-1
Clearing Nummer	4094
Swift-code (BIC)	CRESCH ZZ 80 A
In favour of	0094-805150-61
	Stiftung für Leberkrankheiten
	UVCM Hepatologie
	Murtenstr. 35
	3008 Bern
	<b>IBAN CH17 0483 5080 5150 6100 0</b>

**Stiftung für Leberkrankheiten**  
Murtenstr. 35, F804  
3008 Bern

*Präsident:*  
Prof. Dr. med. Jean-François Dufour  
[jean-francois.dufour@dbmr.unibe.ch](mailto:jean-francois.dufour@dbmr.unibe.ch)

*Administration:*  
monique.obertin@dbmr.unibe.ch  
Tel. +41 31 632 87 11

